Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. 

Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology.

We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. 

• 00:00 Welcome Brandy Wilkinson and Rikki Feng
• 03:17 GemPharmatech's mission
• 06:26 Why mouse models matter in neurology
• 11:11 Common translation gaps in neurology
• 18:09 Designing proprietary neurological disease models
• 25:45 Building stronger CRO strategic partnerships
• 33:58 An optimistic future of neuroscience research

This episode was produced with the support of GemPharmatech. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• Neurological diseases R&D trends and breakthrough innovations
• Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
• 11 neuroscience biotech companies you should know about